Mounjaro® (tirzepatide) is an injectable antidiabetic agent used for the treatment of type 2 diabetes mellitus, as well as for the treatment of overweight and obesity (in appropriate indications). It is the first drug with dual incretin action - an agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.